Page last updated: 2024-12-09

2-(2,5-dimethylphenoxy)-N-(2-hydroxy-5-methylphenyl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(2,5-dimethylphenoxy)-N-(2-hydroxy-5-methylphenyl)acetamide is a **synthetic compound** that has been investigated for its potential **biological activity**. Here's a breakdown of its structure and possible importance:

**Structure:**

* **2-(2,5-dimethylphenoxy):** This part of the molecule indicates a phenoxy group (an oxygen atom attached to a benzene ring) with two methyl groups attached to the benzene ring in positions 2 and 5.
* **Acetamide:** This part represents the basic structure of an amide, with a carbonyl group (C=O) connected to a nitrogen atom.
* **N-(2-hydroxy-5-methylphenyl):** This tells us that the nitrogen of the amide is linked to a 2-hydroxy-5-methylphenyl group, which is a phenol (an aromatic ring with a hydroxyl group) with a methyl group at position 5.

**Importance for Research:**

* **Potential Anti-Inflammatory Activity:** The presence of the phenoxy and phenolic groups, along with the amide structure, suggests that the molecule could potentially interact with various biological targets involved in inflammation. Further research is needed to confirm this.
* **Possible Antimicrobial Activity:** The compound might possess antimicrobial properties due to the presence of the aromatic rings and the potential for hydrogen bonding interactions with bacterial cell membranes.
* **Lead Compound for Drug Development:** If the compound shows promising biological activity in preclinical studies, it could act as a lead compound for the development of new drugs for inflammation, infections, or other conditions.

**Important Note:** The specific biological activity and potential applications of 2-(2,5-dimethylphenoxy)-N-(2-hydroxy-5-methylphenyl)acetamide require further investigation and validation through rigorous scientific research.

**To understand the compound's importance, consider these questions:**

* **Has the compound been tested for biological activity in laboratory settings?**
* **What specific biological targets does it interact with?**
* **Are there any known side effects or toxicity associated with this compound?**

**Researching the compound further:**

* **PubMed:** You can find relevant research papers on PubMed by searching for the compound's name or its structure.
* **Scientific Databases:** Use scientific databases like SciFinder, Reaxys, or PubChem to find information about its synthesis, properties, and biological activity.

Remember, research is an ongoing process, and it's always important to consult reliable scientific sources for the latest information and interpretation of research findings.

Cross-References

ID SourceID
PubMed CID977208
CHEMBL ID1371372
CHEBI ID123379

Synonyms (16)

Synonym
2-(2,5-dimethylphenoxy)-n-(2-hydroxy-5-methylphenyl)acetamide
smr000075767
MLS000063852 ,
STK224528
SR-01000272871-3
CHEBI:123379
AKOS003318616
HMS2317I16
bdbm71820
2-(2,5-dimethylphenoxy)-n-(2-hydroxy-5-methyl-phenyl)acetamide
2-(2,5-dimethylphenoxy)-n-(5-methyl-2-oxidanyl-phenyl)ethanamide
cid_977208
CHEMBL1371372
Q27213089
sr-01000272871
SR-01000272871-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anilideAny aromatic amide obtained by acylation of aniline.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
regulator of G-protein signaling 4Homo sapiens (human)Potency79.43280.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.01190.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
huntingtin isoform 2Homo sapiens (human)Potency0.05010.000618.41981,122.0200AID1688
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency21.19230.168316.404067.0158AID720504
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gli1Mus musculus (house mouse)IC50 (µMol)3.34000.02704.293911.4000AID602464
protein Wnt-3a precursorMus musculus (house mouse)IC50 (µMol)50.00000.44104.995214.8000AID651570
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)260.00000.160024.4900236.5000AID435004
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]